BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

660 related articles for article (PubMed ID: 31405848)

  • 1. Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease.
    Valenzi E; Bulik M; Tabib T; Morse C; Sembrat J; Trejo Bittar H; Rojas M; Lafyatis R
    Ann Rheum Dis; 2019 Oct; 78(10):1379-1387. PubMed ID: 31405848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease.
    Jung SM; Park KS; Kim KJ
    Ann Rheum Dis; 2022 Jan; 81(1):108-116. PubMed ID: 34380701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myofibroblast transcriptome indicates SFRP2
    Tabib T; Huang M; Morse N; Papazoglou A; Behera R; Jia M; Bulik M; Monier DE; Benos PV; Chen W; Domsic R; Lafyatis R
    Nat Commun; 2021 Jul; 12(1):4384. PubMed ID: 34282151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disparate Interferon Signaling and Shared Aberrant Basaloid Cells in Single-Cell Profiling of Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease.
    Valenzi E; Tabib T; Papazoglou A; Sembrat J; Trejo Bittar HE; Rojas M; Lafyatis R
    Front Immunol; 2021; 12():595811. PubMed ID: 33859634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical Role of LMCD1 in Promoting Profibrotic Characteristics of Lung Myofibroblasts in Experimental and Scleroderma-Associated Lung Fibrosis.
    Bogatkevich GS; Atanelishvili I; Bogatkevich AM; Silver RM
    Arthritis Rheumatol; 2023 Mar; 75(3):438-448. PubMed ID: 36103378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease.
    Lindahl GE; Stock CJ; Shi-Wen X; Leoni P; Sestini P; Howat SL; Bou-Gharios G; Nicholson AG; Denton CP; Grutters JC; Maher TM; Wells AU; Abraham DJ; Renzoni EA
    Respir Res; 2013 Aug; 14(1):80. PubMed ID: 23915349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic Regulation of Profibrotic Macrophages in Systemic Sclerosis-Associated Interstitial Lung Disease.
    Papazoglou A; Huang M; Bulik M; Lafyatis A; Tabib T; Morse C; Sembrat J; Rojas M; Valenzi E; Lafyatis R
    Arthritis Rheumatol; 2022 Dec; 74(12):2003-2014. PubMed ID: 35849803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial Cells Expressing Endothelial and Mesenchymal Cell Gene Products in Lung Tissue From Patients With Systemic Sclerosis-Associated Interstitial Lung Disease.
    Mendoza FA; Piera-Velazquez S; Farber JL; Feghali-Bostwick C; Jiménez SA
    Arthritis Rheumatol; 2016 Jan; 68(1):210-7. PubMed ID: 26360820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?
    Jimenez SA; Piera-Velazquez S
    Matrix Biol; 2016 Apr; 51():26-36. PubMed ID: 26807760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wnt/β-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells.
    Wei J; Fang F; Lam AP; Sargent JL; Hamburg E; Hinchcliff ME; Gottardi CJ; Atit R; Whitfield ML; Varga J
    Arthritis Rheum; 2012 Aug; 64(8):2734-45. PubMed ID: 22328118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Netrin-1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin-Induced Pulmonary Fibrosis.
    Sun H; Zhu Y; Pan H; Chen X; Balestrini JL; Lam TT; Kanyo JE; Eichmann A; Gulati M; Fares WH; Bai H; Feghali-Bostwick CA; Gan Y; Peng X; Moore MW; White ES; Sava P; Gonzalez AL; Cheng Y; Niklason LE; Herzog EL
    Arthritis Rheumatol; 2016 May; 68(5):1251-61. PubMed ID: 26749424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease.
    Stock CJW; De Lauretis A; Visca D; Daccord C; Kokosi M; Kouranos V; Margaritopoulos G; George PM; Molyneaux PL; Nihtyanova S; Chua F; Maher TM; Ong V; Abraham DJ; Denton CP; Wells AU; Wain LV; Renzoni EA
    Clin Rheumatol; 2020 Apr; 39(4):1173-1179. PubMed ID: 31916109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity.
    Cutolo M; Gotelli E; Montagna P; Tardito S; Paolino S; Pizzorni C; Sulli A; Smith V; Soldano S
    Arthritis Res Ther; 2021 Aug; 23(1):205. PubMed ID: 34344444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
    Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
    Front Immunol; 2020; 11():1990. PubMed ID: 33013852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.
    Khanna D; Tashkin DP; Denton CP; Renzoni EA; Desai SR; Varga J
    Am J Respir Crit Care Med; 2020 Mar; 201(6):650-660. PubMed ID: 31841044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression meta-analysis reveals aging and cellular senescence signatures in scleroderma-associated interstitial lung disease.
    Yang MM; Lee S; Neely J; Hinchcliff M; Wolters PJ; Sirota M
    Front Immunol; 2024; 15():1326922. PubMed ID: 38348044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease.
    Soldano S; Smith V; Montagna P; Gotelli E; Campitiello R; Pizzorni C; Paolino S; Sulli A; Cere A; Cutolo M
    Arthritis Res Ther; 2024 Mar; 26(1):74. PubMed ID: 38509595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis.
    Christmann RB; Sampaio-Barros P; Stifano G; Borges CL; de Carvalho CR; Kairalla R; Parra ER; Spira A; Simms R; Capellozzi VL; Lafyatis R
    Arthritis Rheumatol; 2014 Mar; 66(3):714-25. PubMed ID: 24574232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-155 in the progression of lung fibrosis in systemic sclerosis.
    Christmann RB; Wooten A; Sampaio-Barros P; Borges CL; Carvalho CR; Kairalla RA; Feghali-Bostwick C; Ziemek J; Mei Y; Goummih S; Tan J; Alvarez D; Kass DJ; Rojas M; de Mattos TL; Parra E; Stifano G; Capelozzi VL; Simms RW; Lafyatis R
    Arthritis Res Ther; 2016 Jul; 18(1):155. PubMed ID: 27377409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrinsic Deregulation of Vascular Smooth Muscle and Myofibroblast Differentiation in Mesenchymal Stromal Cells from Patients with Systemic Sclerosis.
    Hegner B; Schaub T; Catar R; Kusch A; Wagner P; Essin K; Lange C; Riemekasten G; Dragun D
    PLoS One; 2016; 11(4):e0153101. PubMed ID: 27054717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.